Latest revenue
$40.7M
as of 2025-12-31
Latest net income
$-10.6M
as of 2025-12-31
Net margin
-26.0%
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Retail-Drug Stores and Proprietary Stores (5 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think PETS is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $36.3M
- Enterprise value
- $9.4M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.11×
- Dividend yield
- 0.0%
- 52-wk high
- $4.32
- 52-wk low
- $1.57
- Beta
- —
- Shares out
- 21.4M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
ITEM 1. BUSINESS GENERAL PetMed Express, Inc. and subsidiaries, d/b/a PetMeds®, and as parent company of PetCareRx®, is a pioneer in pet healthcare, building a consumer-first digital platform in 1996 that transformed the way customers fulfill pet medications. Nearly thirty years later, as a leading nationwide direct-to-consumer pet health and wellness retailer, the Company markets and sells directly to consumers through its websites (Petmeds.com and PetCareRx.com), customer contact center (1-800-PetMeds), and mobile applications (iOS and Android). The Company provides access to top branded pharmaceuticals, generic medications, compounded prescription medications, pharmacy fulfillment, and…
AI summary unavailable — showing raw filing excerpt
Generated from PETS's filing dated 2025-10-14
Key risks
ITEM 1A. RISK FACTORS Our operations and financial results are subject to various risks and uncertainties, including those described below, that could materially and adversely affect our business, financial condition, operating results and the trading price of our common stock. Because of the following factors, as well as other factors affecting the Company’s results of operations and financial condition, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods. This discussion of risk factors contains forward-looking statements. This section should…
AI summary unavailable — showing raw filing excerpt
Generated from PETS's filing dated 2025-10-14
Profitability
Gross margin
30.5%
1.0%Operating margin
-0.7%
76.8%Net margin
-2.8%
4.0%Return on equity
-7.4%
4.5%Return on assets
-4.2%
4.0%Leverage
Debt / equity
0.75×
1.3%Debt / assets
42.7%
0.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | $40.7M | -21.7% | $-10.6M | -1392.6% | -26.0% |
Q3 2025 2025-09-30 | $44.4M | -23.6% | $-8.5M | -466.3% | -19.2% |
Q1 2025 2025-03-31 | $49.0M | -26.3% | $-11.6M | -159.9% | -23.8% |
Q4 2024 2024-12-31 | $52.0M | -20.4% | $-707.0K | +65.1% | -1.4% |
Q3 2024 2024-09-30 | $58.0M | -18.2% | $2.3M | +3422.9% | 4.0% |
Q2 2024 2024-06-30 | $68.0M | -13.2% | $3.8M | +523.2% | 5.5% |
Q1 2024 2024-03-31 | $66.5M | — | $-4.5M | — | -6.7% |
Q4 2023 2023-12-31 | $65.3M | — | $-2.0M | — | -3.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Retail-Drug Stores and Proprietary Stores · SIC 5912
Your notes
Keep private notes on PETS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$954.9K
Insider selling
$0
Net activity
+$954.9K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns PETS
Institutional value
$6.8M
Total shares held
2.9M
Distinct holders
25
-27 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 831.4K | $1.9M | — | New |
| 2 | FEDERATED HERMES, INC. | 666.8K | $1.5M | +39.1K (+6.2%) | Added |
| 3 | BlackRock, Inc. | 551.7K | $1.3M | +3.7K (+0.7%) | Added |
| 4 | UBS Group AG | 233.7K | $532.8K | -96.0K (-29.1%) | Trimmed |
| 5 | DIMENSIONAL FUND ADVISORS LP | 207.8K | $473.7K | -198.1K (-48.8%) | Trimmed |
| 6 | Formidable Asset Management, LLC | 105.2K | $336.6K | +12.1K (+13.0%) | Added |
| 7 | VANGUARD FIDUCIARY TRUST CO | 109.7K | $250.1K | — | New |
| 8 | GROUP ONE TRADING LLC | 71.1K | $162.1K | +68.0K (+2197.1%) | Added |
| 9 | UMB Bank, n.a. | 60.0K | $136.8K | +0 (+0.0%) | No change |
| 10 | BLAIR WILLIAM & CO/IL | 30.4K | $69.3K | — | New |
| 11 | SEI INVESTMENTS CO | 23.0K | $52.4K | +6.8K (+42.0%) | Added |
| 12 | JANE STREET GROUP, LLC | 18.5K | $42.2K | — | New |
| 13 | BNP PARIBAS FINANCIAL MARKETS | 9.1K | $20.8K | +334 (+3.8%) | Added |
| 14 | Vanguard Global Advisers, LLC | 8.1K | $18.5K | — | New |
| 15 | SBI Securities Co., Ltd. | 1.2K | $2.8K | +0 (+0.0%) | No change |
| 16 | Bank & Trust Co | 901 | $2.1K | +0 (+0.0%) | No change |
| 17 | JPMORGAN CHASE & CO | 804 | $1.8K | — | New |
| 18 | Golden State Equity Partners | 614 | $1.4K | — | New |
| 19 | MCF Advisors LLC | 400 | $912 | +0 (+0.0%) | No change |
| 20 | WELLS FARGO & COMPANY/MN | 301 | $686 | -175 (-36.8%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once PETS's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.